Free tool
FAERS Monitor: Fabrazyme
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103979 or its brand name (Fabrazyme, Agalsidase Beta). Reports on generic versions are filed under their own applications.
Reports
9,357
Serious
4,797
51% of reports
Hospitalization
2,507
Death reported
703
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia526
- pain514
- malaise497
- chills481
- nausea477
- fatigue433
- dyspnoea428
- headache382
- vomiting378
- weight decreased350
- pain in extremity321
- infusion related reaction301
- dizziness290
- weight increased287
- condition aggravated275
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 259 |
| 2005 | 312 |
| 2006 | 197 |
| 2007 | 169 |
| 2008 | 181 |
| 2009 | 170 |
| 2010 | 187 |
| 2011 | 193 |
| 2012 | 175 |
| 2013 | 313 |
| 2014 | 782 |
| 2015 | 590 |
| 2016 | 473 |
| 2017 | 588 |
| 2018 | 508 |
| 2019 | 468 |
| 2020 | 331 |
| 2021 | 480 |
| 2022 | 630 |
| 2023 | 642 |
| 2024 | 619 |
| 2025 | 575 |
| 2026 | 515 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,802 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 301 | 10.2 | 9.2 | 2,500 |
| chillsSignal | 481 | 9.3 | 8.5 | 3,539 |
| pyrexiaSignal | 526 | 3.4 | 3.1 | 912 |
| weight increasedSignal | 287 | 2.9 | 2.6 | 354 |
| weight decreasedSignal | 350 | 2.8 | 2.5 | 414 |
| malaiseSignal | 497 | 2.5 | 2.3 | 476 |
| pain in extremitySignal | 321 | 2.5 | 2.2 | 278 |
| condition aggravatedSignal | 275 | 2.0 | 1.8 | 146 |
| pain | 514 | 1.9 | 1.7 | 218 |
| vomiting | 378 | 1.8 | 1.6 | 139 |
| dyspnoea | 428 | 1.7 | 1.5 | 126 |
| headache | 382 | 1.4 | 1.2 | 39 |
| nausea | 477 | 1.4 | 1.2 | 46 |
| dizziness | 290 | 1.3 | 1.2 | 21 |
| fatigue | 433 | 1.3 | 1.1 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.